WHO ICTRP trial
Fludarabine/Rituximab combined with escalating doses of Lenalidomide in…
EUCTR2011-004912-43-AT · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2011-004912-43-AT |
|---|---|
| Public title | Fludarabine/Rituximab combined with escalating doses of Lenalidomide in untreated chronic lymphocytic leukemia (CLL) |
| Scientific title | Fludarabine/Rituximab combined with escalating doses of Lenalidomide in untreated chronic lymphocytic leukemia (CLL) – a dose-finding study with escalating starting dose of Lenalidomide and concomitant evaluation of safety and efficacy |
| Primary sponsor | Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Austria |
| Conditions | Untreated chronic lymphocytic leukaemia (CLL) MedDRA version: 14.1 Level: LLT Classification code 10003946 Term: B-Lymphocytic, CLL (Kiel Classification) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts… |
| Interventions | Trade Name: Revlimid 5 mg Pharmaceutical Form: Capsule, hard INN or Proposed INN: LENALIDOMIDE CAS Number: 191732-72-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Trade Name: Revlimid 10 mg… |
| Registration date | May 22, 2012 |
| Secondary IDs | AGMT_CLL-9;RV-CLL-AGMT-0710 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: